A cell‐penetrating CD40‐TRAF2,3 blocking peptide diminishes inflammation and neuronal loss after ischemia/reperfusion

While the administration of anti‐CD154 mAbs in mice validated the CD40‐CD154 pathway as a target against inflammatory disorders, this approach caused thromboembolism in humans (unrelated to CD40 inhibition) and is expected to predispose to opportunistic infections. There is a need for alternative ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Portillo, Jose‐Andres C., Yu, Jin‐Sang, Hansen, Samuel, Kern, Timothy S., Subauste, M. Cecilia, Subauste, Carlos S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101361/
https://www.ncbi.nlm.nih.gov/pubmed/33675257
http://dx.doi.org/10.1096/fj.201903203RR

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101361/
https://www.ncbi.nlm.nih.gov/pubmed/33675257
http://dx.doi.org/10.1096/fj.201903203RR

Ejemplares similares